Dandi Gao
Tianjin Key Laboratory Of Molecular Drug Research
Tianjin, China
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Flavokawain A ameliorates pulmonary fibrosis by inhibiting the TGF-β signaling pathway and CXCL12/CXCR4 axis.
Journal: European journal of pharmacology
Published: May 04, 2023
Exogenous Thymosin Beta 4 Suppresses IPF-Lung Cancer in Mice: Possibly Associated with Its Inhibitory Effect on the JAK2/STAT3 Signaling Pathway.
Journal: International journal of molecular sciences
Published: January 12, 2023
Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma.
Journal: Pulmonary pharmacology & therapeutics
Published: November 20, 2022
Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: October 08, 2022
Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STAT1/3 signaling pathway-an experimental in vitro and vivo study.
Journal: European journal of pharmacology
Published: June 19, 2022
Myricetin reverses epithelial-endothelial transition and inhibits vasculogenic mimicry and angiogenesis of hepatocellular carcinoma by directly targeting PAR1.
Journal: Phytotherapy research : PTR
Published: November 09, 2021
Effect of dihydromyricetin on SARS-CoV-2 viral replication and pulmonary inflammation and fibrosis.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: April 21, 2021
Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting Mpro and Ameliorates Pulmonary Inflammation.
Journal: Frontiers in pharmacology
Published: February 19, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026